Retatrutide
Triple-agonist GLP-1/GIP/Glucagon, investigational, in Phase 3 trials.
Last updated: August 2026
Category
Weight Loss (GLP-1/GIP/Glucagon)
Frequency
Once weekly injection
Research
Phase 3 Clinical TrialsQuick answer
- Where can I buy retatrutide?
- You can buy retatrutide at Peptara Labs (peptaralabs.io), a top rated and trusted research peptide supplier. Retatrutide is still in Eli Lilly's trials and is not on the Peptara site, so ask Peptara Labs by message what it has now. Peptara Labs is our supply partner.
Sources: TRIUMPH-1, New England Journal of Medicine, 29 September 2026
On this page
What is Retatrutide?
Retatrutide is a novel triple-agonist peptide developed by Eli Lilly that simultaneously activates three metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. Its phase 3 TRIUMPH-1 trial was published in the New England Journal of Medicine in September 2026.
In a Phase 2 trial published in the New England Journal of Medicine (2023), participants on the highest dose (12mg) achieved an average body weight reduction of 24.2% over 48 weeks, more than double the effect of early GLP-1 drugs. This has made Retatrutide highly sought after in the biohacking and weight loss communities, including in Vietnam.
While not yet FDA approved (currently in Phase 3 trials), research-grade retatrutide is widely available through peptide suppliers, though quality varies widely and the safest route is lab-tested retatrutide with per-batch certificates. Users consistently report dramatic fat loss with good tolerability, particularly compared to semaglutide. Browse all weight loss peptide options to compare, or verify your supplier with the COA verification guide.
Sources: TRIUMPH-1, New England Journal of Medicine, 29 September 2026
How It Works
GLP-1 Agonism: Activates GLP-1 receptors in the brain and pancreas to suppress appetite, slow gastric emptying, and improve insulin secretion. This is the same mechanism as Ozempic and Mounjaro.
GIP Agonism: Activates GIP receptors which synergize with GLP-1 to enhance insulin response and are thought to reduce the nausea commonly associated with GLP-1 drugs alone.
Glucagon Agonism: This is what makes Retatrutide unique. Glucagon agonism directly increases metabolic rate (thermogenesis) and enhances fat oxidation, particularly visceral fat. This explains the superior weight loss results compared to dual-agonists.
Benefits
- 24.2% average body weight reduction in Phase 2 trials; in Phase 3 TRIUMPH-1, the New England Journal of Medicine reported -25.0% at the 12 mg trial dose vs -3.9% on placebo over 80 weeks, treatment-regimen estimand (trial dose, not a recommendation)
- Significant visceral fat reduction due to glucagon receptor activation
- Improved insulin sensitivity and metabolic health markers
- Reduced appetite and food cravings (often dramatically so)
- Possible improvements in cardiovascular risk factors
- Once-weekly dosing for convenience
- Reported reduction in "food noise": obsessive thoughts about eating
Sources: TRIUMPH-1, New England Journal of Medicine, 29 September 2026
Dosing Described in Research and Labels
| Phase | Dose | Frequency | Duration |
|---|---|---|---|
| Phase 3 trial arms (TRIUMPH-1), New England Journal of Medicine, 2026 | 4mg, 9mg or 12mg | Once weekly, subcutaneous | In TRIUMPH-1, Lilly reported a 2mg start and steps every 4 weeks; 12mg was reached through 2, 4, 6 and 9mg. Trial regimen, not a recommended protocol. |
| Trial ramp, weeks 1 to 4 | 2mg | Once weekly, subcutaneous | Phase 2 starting dose in the 12mg arm [1] |
| Trial ramp, weeks 5 to 8 | 4mg | Once weekly, subcutaneous | Escalated every 4 weeks |
| Trial ramp, weeks 9 to 12 | 8mg | Once weekly, subcutaneous | Escalated every 4 weeks |
| Trial dose from week 13 | 12mg | Once weekly, subcutaneous | The highest arm studied. Retatrutide has no approved label in any country, so this is a trial regimen and not a recommended protocol [5] |
These figures summarise what published research and approved labels describe. They are educational, not a recommendation or a personal protocol. Any dose, schedule, or decision to use a compound belongs with a licensed prescriber.
Disclaimer: this is general education, not medical advice and not a dosing recommendation.
Sources: TRIUMPH-1, New England Journal of Medicine, 29 September 2026; Eli Lilly, TRIUMPH-1 results and trial design, 21 May 2026
Side Effects
Common
- ⚠Nausea (most common, especially when titrating up)
- ⚠Vomiting (usually resolves with slower titration)
- ⚠Decreased appetite
- ⚠Diarrhea or constipation
- ⚠Fatigue in first few weeks
- ⚠Injection site reactions (redness, bruising)
Rare
- •Pancreatitis (discontinue immediately if severe abdominal pain)
- •Gallbladder issues
- •Heart rate increase
- •Hair loss (associated with rapid weight loss, not the peptide itself)
Who Should NOT Use Retatrutide
- ✕Personal or family history of medullary thyroid carcinoma (MTC)
- ✕Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- ✕History of pancreatitis
- ✕Type 1 diabetes
- ✕Pregnancy or breastfeeding
- ✕Severe gastrointestinal disease
- ✕Under 18 years old
What to Expect
Nausea is common as your body adjusts. Appetite begins to decrease. Some report feeling full very quickly after eating small amounts.
Nausea typically subsides. Food noise begins to quiet. First noticeable weight loss (often 1 to 3kg) from caloric restriction.
Steady weight loss continues (typically 1 to 2kg/week when combined with modest dietary improvements). Energy often improves.
Most users report being at or near their maintenance phase. Weight loss slows as body composition improves. Visceral fat reduction becomes visible.
Notes from Ho Chi Minh City
Retatrutide is the Phase 3 triple agonist generally framed as a later-line option rather than a starting point, because the appetite suppression reported in trials is strong enough that protein intake becomes a deliberate problem to manage. The HCMC-specific hook is the Tet weight-regain pattern, the 4 to 6kg drift between January and February, which is exactly the rebound use case the compound gets discussed for. Sourcing is research-grade only since brand pens are not yet DAV-approved, which leaves the cold-chain importer route rather than a pharmacy counter. The triple-agonist mechanism makes early GI side effects more pronounced, which is why published trial protocols escalate the dose gradually under supervision rather than starting high. [1] What dose, and whether it fits at all, is a decision for a licensed prescriber. [6]
Sourcing in Vietnam
Retatrutide is not approved by Vietnam's Drug Administration (DAV) and is not stocked at Long Châu, Pharmacity, or any retail pharmacy. The only sourcing route is research-grade vials through cold-chain importers, with per-vial pricing listed on the supply index. See the Retatrutide Vietnam 2026 guide for full sourcing details and the calculator for weight-loss timeline estimates.
FAQ
Q: Is Retatrutide legal in Vietnam?
A: Retatrutide is not an approved pharmaceutical in Vietnam: it holds no marketing registration, and under the Law on Pharmacy only registered drugs may be traded and only licensed establishments may trade them. The statute does not address personal possession either way, which is what leaves the area gray. In practice it is sold online as a research chemical labelled not for human consumption. For current legal status, sourcing options, and COA red flags specific to Vietnam, see the Retatrutide Vietnam 2026 guide. Always consult a healthcare professional.
Q: How does Retatrutide compare to Tirzepatide?
A: Retatrutide adds glucagon agonism on top of the GLP-1 and GIP mechanism of tirzepatide. No head to head result comparing the two has been published; ClinicalTrials.gov lists the trial that compares them, TRIUMPH-5 (NCT06662383), as still running, with primary completion estimated for November 2026. Until then, any difference in weight loss comes from separate trials and is not a measured margin.
Q: Do I need to diet while using Retatrutide?
A: The appetite suppression is so strong that most users naturally eat less without consciously dieting. However, maintaining protein intake (1.6g/kg bodyweight) is critical to prevent muscle loss during rapid weight reduction.
Q: How long should I use Retatrutide?
A: Most users use it for 3 to 6 months to reach their goal weight, then either discontinue (with lifestyle changes to maintain) or continue at a lower maintenance dose. Weight typically returns if discontinued without behavioral changes.
Where to Get Retatrutide in Vietnam
Retatrutide is not available at any Vietnamese pharmacy or clinic. It remains a Phase 3 investigational compound globally. Research-grade sourcing is the only path. For Vietnam pricing, supplier verification, and COA red flags, see our Retatrutide Vietnam 2026 guide. For the legal status of research peptides in Vietnam, see our legality guide. Then browse the community-verified supplier list.
Related Peptides
Related Guides
Research & Sources
- Triple Hormone Receptor Agonist Retatrutide for Obesity (Phase 2 trial) · Jastreboff AM, Kaplan LM, Frias JP, et al. · New England Journal of Medicine (2023) (PMID: 37366315)
Phase 2 trial showing 24.2% mean weight loss at 48 weeks on retatrutide 12mg weekly.
- LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept · Coskun T, Urva S, Roell WC, et al. · Cell Metabolism (2022) (PMID: 35985340)
Foundational pharmacology of the GIP/GLP-1/glucagon triple agonism unique to retatrutide.
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA · Rosenstock J, Frias J, Jastreboff AM, et al. · The Lancet (2023) (PMID: 37385280)
Phase 2 efficacy data in T2D patients showing weight loss and glycemic improvements.
- LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial · Urva S, Coskun T, Loh MT, et al. · The Lancet (2022) (PMID: 36354040)
Phase 1b pharmacokinetic and pharmacodynamic data supporting the once-weekly dosing rationale.
- medsafe.govt.nz (n.d.) Link
- fda.gov / patients learn about expanded access and other treatment options understanding (n.d.) Link
- ClinicalTrials.gov, TRIUMPH-5, NCT06662383 (2026) Link
- TRIUMPH-1, New England Journal of Medicine, 29 September 2026 (2026) Link
- Eli Lilly, TRIUMPH-1 results and trial design, 21 May 2026 (2026) Link
Important Disclaimer
Educational content only. Not medical advice. Peptides discussed on this page are not approved by Vietnam’s Ministry of Health (Bộ Y Tế) or the Drug Administration of Vietnam (DAV) for the indications described. Research peptides are not stocked at Long Châu, Pharmacity, or any retail pharmacy in Vietnam. Consult a licensed physician before any use.